Each Korean Medical Company serves the CERTIFICATE OF PARTICIPATION and MEMORIAL PHOTO.
B-3rd Floor, Global R&D Center, 22, Daewangpangyo-ro
712beon-gil, Bundang-gu, Seongnam-si,
WONTECH, History of Korean Medical Laser Industry.
We are now leaping into a global leader in laser medical devices.
WONTECH has been concentrating on medical lasers for nearly 20 years. Increasing the quality of life via constant challenge and innovation, as a company providing healthy solutions to human beings, WONTECH has been listed in a world-class 300. Beyond a company in a world-class 300, we plan to be a hidden champion as a global brand.
WONTECH Co., Ltd. established in 1999, grows up steadily and leads a medical laser equipment & Ultrasound (HIFU) market.
Particularly, WONTECH realized a limitation of domestic techniques, which depend mostly on foreign technology when its establishment, invests continuously to achieve localization and development of techniques by composing 50% of employees in R&D. Based on our technical power and high tech facilities, WONTECH has expanded the market into not only Domestics, but also China, America, Europe, Middle East and other overseas market, continuing to enhance the global outstanding corporation.
With an advanced techniques, WONTECH’s equipment are facilitated in a variety of area including Skin Aesthetics, Fat Reduction, Surgical usage and still research and develop devices using Laser and Ultra sound to approach human health promotion in advance.
WONTECH will continuously improve all process from research, development to manufacturing and A/S of all our products with professional technology and developments to provide the best value.
To keep constant technical innovation, transparent management system and social responsibility, WONTECH has kept ties with regional society and will put efforts on standing as a Global Leader in worldwide.
WONTECH is the world’s first company manufactures both Nd:YAG and Alexandrite Picosecond Laser.
Picosecond Laser is the one all Aesthetic Medical Laser companies competing for World’s first, WONTECH has developed Nd:YAG and even Alexandrite as well.
The most strict US FDA has admitted PICOCARE of WONTECH From hometown of laser, the biggest aesthetic medical market America, PICOCARE cleared FDA It is Asia’s first, and just few world widely.
“Leader of Pico Laser, WONTECH”
8~10F, 626, Teheran-ro,
Medytox, a global biopharmaceutical company, is at the forefront of efforts to build a better future with ceaseless R&D.
Since the launch of botulinum toxin type A Meditoxin® in 2006 (trade name: Neuronox®, Siax®, Botulift®, Cunox®, Acebloc® and Meditoxin®), Medytox has shown a dramatic growth. Medytox reached nearly 40% of market share in Korea since 2009 and is expected to increase even further with various indications being included. The global botulinum toxin market continues to grow and is expected to further expand to not only medical aesthetics market but also therapeutic market. Medytox is stunning the world with high market share in the global botulinum market.
With the goal of penetrating to the US and Europe, we plan to exceed 10% of the market share in the global market along with the launch of the currently developing new type botulinum toxin products.
In the future, Medytox will grow as the leader of the biopharmaceutical industry by challenging ourselves with passion for the global market.
Neuronox® is Korea’s first and the fourth botulinum toxin type A product in the world, launched in 2006.
Neuronox® is a representative botulinum toxin type A product of Medytox that is being exported to over 60 countries. Neuronox® ranks No.1 in market share in Korea and has gained significant market share in many other countries. (Being sold worldwide under different brand names including Siax®, Botulift®, Cunox®, Tonytox® and Meditoxin®)
Neuronox® offers choices by providing a range of product units including 50, 100, 150 and 200.
Neuronox® Backed up by efficacy and safety proven through clinical trials, Neuronox® has recently reached the sales of over 1,200 million vials*, and the sales is still steadily growing.
*Figures from Medytox. (2018.11)
INNOTOX® is the world’s first liquid formulation of botulinum toxin type A product, develped and launched in 2014.
INNOTOX® is an innovative product which has been developed by totally excluding animal-derived ingredients and human serum albumin in order to enhance product safety. At the same time, it is easy to prepare since no dilution is necessary for adminisration. Currently INNOTOX® is being sold in Korea and Japan and it is emerging as the product to show our distinguished R&d capabilities.
Medytox has obtained Coretox® marketing approval in 2016, which was developed as the 3rd botulinum toxin type A product for the company. Coretox® is an advanced new botulinum toxin type A product that excludes animal derivatives, human serum albumin and non-toxin proteins from its ingredients. It prevents the immune system from developing antibodies that would eventually wear down the effects of botulinum toxin type A.
Neuramis® is the hyaluronic acid dermal filler product developed and launched in 2011. The Neuramis® series Neuramis® Meso(Export Only), Neuramis® Light Lidocaine, Neuramis® Lidocaine, Neuramis® Deep, Neuramis® Deep
Lidocaine, Neuramis® Volume Lidocaine which can be used to add volume and fullness to the skin to correct moderate to severe nasolabial folds, the lines from your nose to the corners of your mouth.
Medytox Company Tour
Medytox is a global Biopharmaceutical Company in Republic of Korea and we prepare Medytox Company Tour to give you a great experience.
Our tour will provide you with the useful information; regarding Neuronox (lyophilized powder) and Innotox (liquid), which are Botulinum toxin Type A products, and Neuramis Series, which is Hyaluroniuc acid filler.
Also, the Speech and Live Demonstration to make you improve your dermatological techniques are prepared.
* 20 attendees only
219 Sowon-ro, Deogyang-gu, Goyang-si, Gyeonggi-do, Korea
LUTRONIC, a leading innovator in advanced aesthetic and medical laser and related technology, was established in 1997 to bring intuitive, robust, versatile devices that are affordable and efficacious to the worldwide medical community. Committed to improving medicine, LUTRONIC partners with key opinion leaders to advance science and ensure the efficacy of its systems. All systems are versatile and offer multiple settings and treatment options for customized treatments, which maximize outcomes for a wide variety of conditions and treatments including: melasma, tattoo removal, soft tissue incision, vascular lesions, hair removal, wrinkle reduction, rejuvenation, body/face contouring, chronic pain, healing and more.
With a focus on physician needs and patient outcomes, LUTRONIC dedicates time and funding toward the development of devices that offer features and improvements not found in today’s market. Devoting more than 20% of revenue to R&D, LUTRONIC holds more than 130 current and pending patents worldwide. With more than 400 employees worldwide, LUTRONIC has offices in the Korea, US, China, Japan, Germany, and France, a worldwide network of distributors, focused R&D centers in both the US and Korea, and is ever expanding.
Our passion is to improve the lives of physicians and their patients by developing innovative solutions that are intuitive, versatile, efficacious and beneficial to society.
|Specialty Treatments||Applications||Applications Cont.|
|Company Name||Daewoong Pharmaceutical|
Daewoong Group is a global healthcare group established in 1945 under the vision to ‘manufacture high quality pharmaceuticals to enhance people’s health and create a healthy society’.
As it is our vision to be a global healthcare group, Daewoong has established 3 manufacturing sites in Indonesia and China and 8 branch offices in China, Japan, Indonesia, Thailand, Vietnam, Philippines, India and USA. Through our global presence, we are actively striving to export our high value added portfolio to the world.
To achieve our mission to provide the most beneficial total solutions in pharmaceuticals and services that contribute to improving the quality of life of valued consumers, we have been reinforcing R&D capacities through the establishment of R&D centers globally in Korea, China, India and Indonesia and focusing on developing new chemical entities, biologics, incrementally modified drugs and high-value added APIs.
|Global Talent Platform Development|
|R&D and Manufacturing Reinforcement|
|Global Business Expansion|
|Strengthening Brand Awareness|
Specialized Manufacturing Sites
Daewoong Pharmaceutical has a number of strategically located manufacturing sites, each of which specializes in various production lines such as depot injection, liquid suspension, biological, and etc.
By achieving global standards, the new cGMP facility will play a crucial role in establishing Daewoong Pharmaceutical as a leading global manufacturer to the worldwide market.
Daewoong has manufactured numerous products launched from global pharmaceutical companies such as Novatis, Sanofi, Abbott and Recipharm. We’ve been proven by their quality assurance based on regular inspections from the products' originators.
Daewoong received the Excellent Manufacturer Award by Korean Quality Management and the President Award by the Korea Standards Association. Daewoong Observes International Environmental, Safety, and Health Standards. (ISO14001 and OHSAS18001 certificates).
High Quality Assurance Daewoong
|Daewoong Pharmaceutical Co., Ltd.|
|[ Active Ingredients ]|
|Prabotulinumtoxin A, 50 / 100 / 150 / 200 Units|
|(Clostridium botulinum toxin type A)|
|[ Indications & Usage ]|
|[ Package ]|
|10vials / Box|
CharacteristicsPatented Technology NABOTA was developed with Daewoong’s 30 years of experience in biotechnology. NABOTA ensures the quality of international standards via its own patented purification process. Patent registration KR 10-1339349(Patented in 2013). Reduced Impurity NABOTA is a highly purified product manufactured with a patented purification process from which impurities are removed as much as possible. Overseas Expansion Excellence in the quality of NABOTA has led to contracts to export the finished product to about 75 countries including the United States and 28 European countries. Active Ingredients Prabotulinumtoxin A, 50 / 100 / 150 / 200 Units (Clostridium botulinum toxin type A). Indications & Usage Temporary improvement in the appearance of moderate to severe glabellar lines(vertical lines between the eyebrows) associated with corrugator muscle and/or procerus muscle activities, in adults aged between 20 to 65. Upper limb spasticity related to stroke in adults over 18 years of age.